SMN2 and proximal spinal muscular atrophy: These therapeutics promote splicing of exon 7 in Survival of Motor Neuron 2 (SMN2) transcripts, thereby increasing the production of functional SMN2 protein, which compensates for the loss of SMN1 as a consequence of mutations in SMA patients.